NAMPT and ovarian carcinoma: The rising interest of NAMPT inhibitors and their ongoing clinical trials make them accessible for repurposing, and in spite of the mixed results of daporinad as a single agent, we believe that they have strong clinical potential for combination therapy, including for treatment of drug-resistant relapse in ovarian cancer patients.